Natco Pharma

55
Hold
  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE987B01026
  • NSEID: NATCOPHARM
  • BSEID: 524816
INR
933.60
-15.65 (-1.65%)
BSENSE

Dec 05

BSE+NSE Vol: 8.82 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationProfit and Loss Results
Results Snapshot
Figures in Cr
Consolidated - Profit And Loss Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
No of Months
12
12
12
12
12
12
Operating Income
4,429.00
3,998.00
2,707.00
1,944.00
2,052.00
1,915.00
Less :Inter divisional transfers
0.00
0.00
0.00
0.00
0.00
0.00
Less: Excise
0.00
0.00
0.00
0.00
0.00
0.00
Net Sales
4,429.00
3,998.00
2,707.00
1,944.00
2,052.00
1,915.00
Expenditure (Ex Depriciation)
Stock Adjustments
-12.00
42.00
-23.00
-16.00
-48.00
-75.00
Raw Materials Consumed
702.00
673.00
651.00
577.00
559.00
456.00
Power & Fuel Cost
93.00
88.00
81.00
76.00
61.00
62.00
Employee Cost
594.00
525.00
486.00
444.00
414.00
375.00
Operating Expenses
210.00
174.00
142.00
140.00
107.00
126.00
General and Administration Expenses
-1.00
-1.00
-1.00
-1.00
-1.00
-1.00
Selling and Distribution Expenses
136.00
153.00
96.00
43.00
34.00
98.00
Cost of Software developments
0.00
0.00
0.00
0.00
0.00
0.00
Miscellaneous Expenses
89.00
131.00
35.00
81.00
43.00
66.00
Expenses Capitalised
0.00
0.00
0.00
0.00
0.00
0.00
Total Expenditure
2,233.00
2,247.00
1,771.00
1,681.00
1,445.00
1,332.00
Operating Profit (PBDIT) excl Other Income
2,196.00
1,751.00
935.00
263.00
606.00
582.00
Other Income
354.00
128.00
104.00
99.00
103.00
107.00
Operating Profit (PBDIT)
2,550.00
1,879.00
1,040.00
362.00
709.00
690.00
Interest
23.00
19.00
14.00
17.00
13.00
21.00
Profit before Depriciation and Tax
2,526.00
1,860.00
1,025.00
344.00
696.00
668.00
Depreciation
235.00
186.00
163.00
142.00
116.00
99.00
Profit Before Taxation & Exceptional Items
2,291.00
1,673.00
861.00
202.00
579.00
568.00
Exceptional Income / Expenses
0.00
0.00
0.00
0.00
0.00
0.00
Profit Before Tax
2,291.00
1,673.00
861.00
202.00
579.00
568.00
Provision for Tax
408.00
285.00
146.00
32.00
137.00
110.00
Profit After Tax
1,883.00
1,388.00
715.00
170.00
442.00
458.00
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
Adj to Profit After Tax
0.00
0.00
0.00
0.00
0.00
0.00
Profit Balance B/F
4,465.00
3,292.00
2,666.00
2,568.00
2,239.00
1,937.00
Profit Available for appropriations
6,351.00
4,680.00
3,381.00
2,738.00
2,680.00
2,397.00
Appropriations
6,351.00
4,680.00
3,381.00
2,738.00
2,680.00
2,397.00
Equity Dividend (%)
300.00%
475.00%
275.00%
225.00%
262.50%
337.50%
Earnings Per Share
105.26
77.24
39.18
9.32
24.20
25.33
Profit And Loss Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Mar 2025 is 10.77% vs 47.72% in Mar 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Mar 2025 is 25.39% vs 87.20% in Mar 2024

stock-summary

Interest

YoY Growth in year ended Mar 2025 is 24.48% vs 32.41% in Mar 2024

stock-summary

Profit After Tax

YoY Growth in year ended Mar 2025 is 35.66% vs 94.09% in Mar 2024

Compare Profit and Loss Results of Natco Pharma
Markets Mojo
Figures in Cr
consolidated - Profit And Loss Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
No of Months
12
12
Operating Income
4,429.00
7,234.00
-2,805.00
-38.78%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
4,429.00
7,234.00
-2,805.00
-38.78%
Expenditure (Ex Depriciation)
Stock Adjustments
-12.00
34.00
-46.00
-135.29%
Raw Materials Consumed
702.00
2,282.00
-1,580.00
-69.24%
Power & Fuel Cost
93.00
154.00
-61.00
-39.61%
Employee Cost
594.00
2,267.00
-1,673.00
-73.80%
Operating Expenses
210.00
528.00
-318.00
-60.23%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
136.00
205.00
-69.00
-33.66%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
89.00
57.00
32.00
56.14%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
2,233.00
6,060.00
-3,827.00
-63.15%
Operating Profit (PBDIT) excl Other Income
2,196.00
1,173.00
1,023.00
87.21%
Other Income
354.00
56.00
298.00
532.14%
Operating Profit (PBDIT)
2,550.00
1,230.00
1,320.00
107.32%
Interest
23.00
240.00
-217.00
-90.42%
Profit before Depriciation and Tax
2,526.00
990.00
1,536.00
155.15%
Depreciation
235.00
368.00
-133.00
-36.14%
Profit Before Taxation & Exceptional Items
2,291.00
621.00
1,670.00
268.92%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
2,291.00
980.00
1,311.00
133.78%
Provision for Tax
408.00
144.00
264.00
183.33%
Profit After Tax
1,883.00
836.00
1,047.00
125.24%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
4,465.00
4,539.00
-74.00
-1.63%
Profit Available for appropriations
6,351.00
5,379.00
972.00
18.07%
Appropriations
6,351.00
5,379.00
972.00
18.07%
Equity Dividend (%)
300%
500%
-200.00
Earnings Per Share
105.26
52.99
52.27
98.64%
Profit And Loss - Net Sales
Net Sales 4,429.50 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 10.77% vs 47.72% in Mar 2024

Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 2,196.00 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 25.39% vs 87.20% in Mar 2024

Profit And Loss - Interest
Interest 23.90 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 24.48% vs 32.41% in Mar 2024

Profit And Loss - Profit After Tax
Profit After Tax 1,883.40 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 35.66% vs 94.09% in Mar 2024